AIM ImmunoTech Inc.
AIM ImmunoTech Inc.
OCALA, FL
Loading...
Price History
Market Data
| Market Cap | 247,559.12 |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | - |
| Current Ratio | 0.53 |
| Currency | USD |
Key Financial Metrics
88,000.00
Revenue
-13.96M
Net Income
-
EPS (Diluted)
-17.21M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-13254.5%
Net Profit Margin
-15861.4%
EBITDA
-11.66M
Returns & Efficiency
Return on Assets (ROA)
-241.4%
Return on Equity (ROE)
-
Dividend Yield
-
EPS
-
Financial Health
Total Assets
5.78M
Total Debt
4.48M
Debt to Equity
-
Current Ratio
0.53
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | OCALA, FL |
| Fiscal Year | 2025 |
Peers
AMGEN INC
AMGN
177.13B
P/E: --
GILEAD SCIENCES INC
GILD
166.13B
P/E: --
166.13B
P/E: --
BIOGEN IDEC INC.
BIIB
27.90B
P/E: --
BIOGEN INC.
BIIB
27.90B
P/E: --
19.11B
P/E: --
MODERNA, INC.
MRNA
18.38B
P/E: --
Moderna, Inc.
MRNA
18.38B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$247.56K
P/E Ratio (TTM)-
Price to Book-
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-13254.5%
Net Margin-15861.4%
ROE-
ROA-241.4%
Leverage & Liquidity
Debt to Equity-
Current Ratio0.53
Total Debt$4.48M
Total Assets$5.78M
Stockholders' Equity$-9.78M
Income Statement (FY 2025)
Revenue$88.00K
Gross Profit-
Operating Income$-11.66M
Net Income$-13.96M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-17.21M
Cash & Equivalents$2.98M
Revenue Growth-48.2%
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 2117 SW HIGHWAY 484 OCALA, FL 32801 |
| Phone | N/A |
| Incorporated | DE, US |
| EIN | 520845822 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 423,178.00 |
| Stockholders' Equity | $-9.78M |
| Cash & Equivalents | $2.98M |
Recent Filings
View All
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-27
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-16
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-16
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-10
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-10
Local
424B3
Prospectus (Rule 424b3)
Prospectus filed under Rule 424(b)(3)
Filed: 2026-02-27
Local
424B4
Prospectus (Rule 424b4)
Prospectus filed under Rule 424(b)(4)
Filed: 2026-02-17
Local
EFFECT
Effectiveness Notice
Notice of effectiveness
Filed: 2026-02-10
Local
S-1/A
Amended IPO Registration
Amendment to IPO registration statement
Filed: 2026-02-10
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-02-06
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-02-05
Local
S-1/A
Amended IPO Registration
Amendment to IPO registration statement
Filed: 2026-01-23
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-01-20
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-17
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-10-29
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | AIM ImmunoTech Inc. |
| Ticker | AIMI |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | OCALA, FL |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 247,559.12 |
| Revenue | 88,000.00 |
| Net Income | -13.96M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | -15861.4% |
| ROE | - |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...